NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026
Rhea-AI Summary
NovaBridge Biosciences (Nasdaq: NBP) announced it will host a webcast on Thursday, August 20, 2026, at 9:00 AM ET / 9:00 PM China Standard Time to discuss recent corporate progress and financial results for the first half ended June 30, 2026.
Investors can access the live and archived webcast via the Upcoming Events section of the Investors page on the NovaBridge website, with separate links for China and other locations. A replay will be available for at least 30 days after the event.
NovaBridge is a global biotechnology company with clinical programs in oncology and ophthalmology, led by candidates givastomig and VIS-101, and focuses on advancing differentiated therapeutic opportunities through tailored development, financing, and partnering strategies.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 24 | Annual meeting notice | Neutral | +0.6% | Annual meeting date, voting eligibility, and shareholder materials were announced. |
| Jun 29 | CEO appointment | Positive | +20.7% | Srishti Gupta became CEO and board member effective July 1, 2026. |
| Jun 16 | FDA designation | Positive | +2.7% | Givastomig received FDA Fast Track Designation in gastric cancer. |
| May 28 | Conference presentation | Neutral | +0.0% | Management scheduled a presentation at the Jefferies healthcare conference. |
| May 12 | Conference presentation | Neutral | -1.9% | Management announced participation in the H.C. Wainwright investor conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive corporate developments were followed by positive 24-hour reactions, while informational conference announcements produced mixed results.
Key Terms
oncology medical
ophthalmology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced that it will hold a webcast on Thursday, August 20, 2026 at 9:00 AM ET/9:00 PM China Standard Time to discuss recent corporate progress and financial results for the first half ended June 30, 2026.
Webcast Information:
- Date: Thursday, August 20, 2026
- Time: 9:00 AM ET/9:00 PM China Standard Time
- Web Access - China: Click here
- Webcast Access – All other locations: Click here
The live and archived webcast can also be accessed by visiting the NovaBridge Biosciences website on the Upcoming Events section of the Investors page. A replay of the webcast will be archived for at least 30 days after the event.
About NovaBridge
NovaBridge Biosciences (Nasdaq: NBP) is a global biotechnology company advancing a portfolio of therapeutic programs in oncology and ophthalmology.. The Company identifies differentiated therapeutic opportunities, generates value-defining clinical evidence, and applies the development, financing, and partnering strategy best suited to each program.
NovaBridge's portfolio includes programs in oncology and ophthalmology, led by givastomig and VIS-101. The Company's objective is to build a sustainable biotechnology company by repeatedly identifying differentiated innovation, advancing it efficiently, and bringing innovative therapies to patients through the path best suited to each opportunity.
For more information, please visit www.novabridge.com and follow us on LinkedIn.
NovaBridge Investor & Media Contacts
NovaBridge Biosciences
+1-240-745-6330
IR@novabridge.com
Bill Begien, VP, Investor Relations
bill.begien@novabridge.com
Jessica Zhang, Director, Public Relations
jessica.zhang@novabridge.com
